SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-23-093725
Filing Date
2023-12-06
Accepted
2023-12-06 16:44:35
Documents
51
Period of Report
2023-06-30

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea189432-6k_nlspharma.htm   iXBRL 6-K 25160
2 CONDENSED FINANCIAL STATEMENTS (UNAUDITED) OF NLS PHARMACEUTICS AS OF JUNE 30, 2 ea189432ex99-1_nlspharma.htm   iXBRL EX-99.1 428532
3 MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERA ea189432ex99-2_nlspharma.htm EX-99.2 167390
  Complete submission text file 0001213900-23-093725.txt   3258250

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE nlsp-20230630.xsd EX-101.SCH 43397
5 XBRL CALCULATION FILE nlsp-20230630_cal.xml EX-101.CAL 23395
6 XBRL DEFINITION FILE nlsp-20230630_def.xml EX-101.DEF 162605
7 XBRL LABEL FILE nlsp-20230630_lab.xml EX-101.LAB 345217
8 XBRL PRESENTATION FILE nlsp-20230630_pre.xml EX-101.PRE 177182
45 EXTRACTED XBRL INSTANCE DOCUMENT ea189432-6k_nlspharma_htm.xml XML 261560
Mailing Address THE CIRCLE 6 8058 ZURICH V8 CH-6370
Business Address THE CIRCLE 6 8058 ZURICH V8 CH-6370 41-41-618-80-00
NLS Pharmaceutics Ltd. (Filer) CIK: 0001783036 (see all company filings)

IRS No.: 000000000 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-39957 | Film No.: 231470165
SIC: 2834 Pharmaceutical Preparations